Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:52:03 UTC |
---|
HMDB ID | HMDB0015615 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Rotigotine |
---|
Description | Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson's disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008. |
---|
Structure | CCCN(CCC1=CC=CS1)C1CCC2=C(C1)C=CC=C2O InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3 |
---|
Synonyms | Value | Source |
---|
2-(N-N-Propyl-N-2-thienylethylamino)-5-hydroxytetralin | HMDB | N 0437, (R)-Isomer | HMDB | N 0437, Hydrochloride, (S)-isomer | HMDB | Neupro | HMDB | N 0437, Hydrochloride, (R)-isomer | HMDB | Rotigotine CDS | HMDB | N 0437, (+-)-Isomer | HMDB | N 0437, (-)-Isomer | HMDB | (+--)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | HMDB | Rotigotine (+-)-form | HMDB | (+)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol | HMDB | Racemic N-0437 | HMDB | Rotigotine | MeSH |
|
---|
Chemical Formula | C19H25NOS |
---|
Average Molecular Weight | 315.473 |
---|
Monoisotopic Molecular Weight | 315.165685117 |
---|
IUPAC Name | 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol |
---|
Traditional Name | rotigotine |
---|
CAS Registry Number | 92206-54-7 |
---|
SMILES | CCCN(CCC1=CC=CS1)C1CCC2=C(C1)C=CC=C2O |
---|
InChI Identifier | InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3 |
---|
InChI Key | KFQYTPMOWPVWEJ-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Tetralins |
---|
Sub Class | Not Available |
---|
Direct Parent | Tetralins |
---|
Alternative Parents | |
---|
Substituents | - Tetralin
- 1-hydroxy-4-unsubstituted benzenoid
- 1-hydroxy-2-unsubstituted benzenoid
- Aralkylamine
- Thiophene
- Heteroaromatic compound
- Tertiary amine
- Tertiary aliphatic amine
- Organoheterocyclic compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.009 g/L | Not Available | LogP | 4.70 | BIOBYTE STARLIST (2009) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Rotigotine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00kb-5940000000-0e75a5000ec3a22e167f | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rotigotine GC-MS (1 TMS) - 70eV, Positive | splash10-00di-9676000000-c2c17a9be9ff518fd1a4 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rotigotine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rotigotine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rotigotine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 10V, Positive-QTOF | splash10-014i-0109000000-619a34c70df0127126a0 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 20V, Positive-QTOF | splash10-03xv-2943000000-f2a166a547875b8aa2f3 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 40V, Positive-QTOF | splash10-01ox-9610000000-df350d204b0f46c67fcf | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 10V, Negative-QTOF | splash10-03di-0019000000-66786ca50da2b4a94ece | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 20V, Negative-QTOF | splash10-0ik9-0196000000-1a48969928fc8b30d7c9 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 40V, Negative-QTOF | splash10-0a4i-9420000000-8c909ccb8e96a48ee1fd | 2017-09-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 10V, Positive-QTOF | splash10-014i-0209000000-15850c28955bfb7c9dc3 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 20V, Positive-QTOF | splash10-02t9-2879000000-5ff2a2216ca834970f0b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 40V, Positive-QTOF | splash10-0292-7900000000-9b4fbb67f22deb78aabf | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 10V, Negative-QTOF | splash10-03di-2009000000-fbc433e758b0515faec6 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 20V, Negative-QTOF | splash10-000t-9102000000-e9be62772b64937e8316 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rotigotine 40V, Negative-QTOF | splash10-01qa-5920000000-c7da667e3b4901cfc8a1 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH: Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007 Dec;22(16):2398-404. [PubMed:17935234 ]
- Chen JJ, Swope DM, Dashtipour K, Lyons KE: Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Pharmacotherapy. 2009 Dec;29(12):1452-67. doi: 10.1592/phco.29.12.1452. [PubMed:19947805 ]
- Perez-Lloret S, Rey MV, Ratti PL, Rascol O: Rotigotine transdermal patch for the treatment of Parkinson's Disease. Fundam Clin Pharmacol. 2013 Feb;27(1):81-95. doi: 10.1111/j.1472-8206.2012.01028.x. Epub 2012 Feb 9. [PubMed:22320451 ]
- de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL: ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1247-61. doi: 10.1517/17425255.2012.708023. Epub 2012 Jul 18. [PubMed:22808933 ]
|
---|